Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v2.4.1.9
Consolidated Statements of Cash Flows (USD $)
 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Contingent Consideration Classified as Equity, Fair Value Disclosure $ 1,820,000us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure  
Non-cash loss on sale of Group DCA 1,906,000us-gaap_OtherNoncashExpense 0us-gaap_OtherNoncashExpense
Gain (Loss) on Disposition of Business 1,200,000us-gaap_GainLossOnSaleOfBusiness  
Other intangible assets, net 47,304,000us-gaap_OtherIntangibleAssetsNet 0us-gaap_OtherIntangibleAssetsNet
Cash Flows From Operating Activities    
Net loss (16,073,000)us-gaap_NetIncomeLoss (4,565,000)us-gaap_NetIncomeLoss
Adjustments to reconcile net income to net cash    
Depreciation and amortization 2,391,000us-gaap_DepreciationDepletionAndAmortization 1,425,000us-gaap_DepreciationDepletionAndAmortization
Deferred taxes (5,035,000)us-gaap_GoodwillSubsequentRecognitionOfDeferredTaxAsset 0us-gaap_GoodwillSubsequentRecognitionOfDeferredTaxAsset
Realignment accrual accretion 142,000us-gaap_AccretionExpense 142,000us-gaap_AccretionExpense
Accretion Expense, Including Asset Retirement Obligations 139,000us-gaap_AccretionExpenseIncludingAssetRetirementObligations 142,000us-gaap_AccretionExpenseIncludingAssetRetirementObligations
Provision for bad debt, net 0us-gaap_ProvisionForDoubtfulAccounts 9,000us-gaap_ProvisionForDoubtfulAccounts
Stock-based compensation 2,124,000us-gaap_ShareBasedCompensation 1,723,000us-gaap_ShareBasedCompensation
Asset impairments - privately held non-controlled entity 2,086,000us-gaap_AssetImpairmentCharges 0us-gaap_AssetImpairmentCharges
Other changes in assets and liabilities:    
(Increase) decrease in accounts receivable (3,422,000)us-gaap_IncreaseDecreaseInAccountsReceivable 8,256,000us-gaap_IncreaseDecreaseInAccountsReceivable
Decrease (increase) in unbilled costs 2,064,000us-gaap_IncreaseDecreaseInUnbilledReceivables (6,027,000)us-gaap_IncreaseDecreaseInUnbilledReceivables
Decrease in other current assets 1,614,000us-gaap_IncreaseDecreaseInOtherCurrentAssets 1,740,000us-gaap_IncreaseDecreaseInOtherCurrentAssets
Decrease in other long-term assets 193,000us-gaap_IncreaseDecreaseInOtherNoncurrentAssets 165,000us-gaap_IncreaseDecreaseInOtherNoncurrentAssets
Increase (decrease) in accounts payable 786,000us-gaap_IncreaseDecreaseInAccountsPayable (1,038,000)us-gaap_IncreaseDecreaseInAccountsPayable
Decrease in unearned contract revenue (929,000)us-gaap_IncreaseDecreaseInDeferredRevenue (5,122,000)us-gaap_IncreaseDecreaseInDeferredRevenue
(Decrease) increase in accrued salaries and bonus (4,248,000)us-gaap_IncreaseDecreaseInAccruedSalaries 2,969,000us-gaap_IncreaseDecreaseInAccruedSalaries
Increase (decrease) in accrued liabilities 1,180,000us-gaap_IncreaseDecreaseInAccruedLiabilities (1,805,000)us-gaap_IncreaseDecreaseInAccruedLiabilities
Decrease in long-term liabilities (1,296,000)us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities (1,384,000)us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities
Net cash used in operating activities (16,378,000)us-gaap_NetCashProvidedByUsedInOperatingActivities (3,512,000)us-gaap_NetCashProvidedByUsedInOperatingActivities
Cash Flows From Investing Activities    
Purchase of property and equipment (2,851,000)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (1,818,000)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Acquisition of diagnostic assets (8,500,000)us-gaap_PaymentsToAcquireProductiveAssets  
Acquisition of RedPath (13,359,000)us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired  
Loan to the Diagnostics Company (655,000)us-gaap_PaymentsForProceedsFromLoansAndLeases  
Investment in privately held non-controlled entity 0us-gaap_PaymentsToAcquireInvestments (1,500,000)us-gaap_PaymentsToAcquireInvestments
Net cash used in investing activities (25,365,000)us-gaap_NetCashProvidedByUsedInInvestingActivities (3,318,000)us-gaap_NetCashProvidedByUsedInInvestingActivities
Cash Flows From Financing Activities    
Proceeds from (Payments for) Other Financing Activities 20,000,000us-gaap_ProceedsFromPaymentsForOtherFinancingActivities  
Cash paid for debt discount and deferred financing costs (557,000)us-gaap_PaymentOfFinancingAndStockIssuanceCosts  
Cash paid for repurchase of restricted shares (228,000)us-gaap_PaymentsForRepurchaseOfCommonStock (314,000)us-gaap_PaymentsForRepurchaseOfCommonStock
Net cash used in financing activities 19,215,000us-gaap_NetCashProvidedByUsedInFinancingActivities (314,000)us-gaap_NetCashProvidedByUsedInFinancingActivities
Net decrease in cash and cash equivalents (22,528,000)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (7,144,000)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents – beginning 45,639,000us-gaap_CashAndCashEquivalentsAtCarryingValue 52,783,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents – ending 23,111,000us-gaap_CashAndCashEquivalentsAtCarryingValue 45,639,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash paid for taxes 115,000us-gaap_IncomeTaxesPaid 235,000us-gaap_IncomeTaxesPaid
Contingent consideration, liability 26,542,000us-gaap_BusinessCombinationContingentConsiderationLiability  
Notes Payable, Noncurrent $ 11,000,000us-gaap_LongTermNotesPayable